文献速递肝肾功能剂量调整特殊人群用药

肾功能或肝损伤对Somapacitan药代动力学和药效学的影响:两项开放标签平行组试验

Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials.
PubMed 文献 · Clin Pharmacokinet · 2021-03-23

两项开放标签平行组试验评估了肾功能或肝损伤对长效生长激素衍生物Somapacitan暴露的影响。受试者接受三次皮下注射0.08 mg/kg,主要终点为末次给药后0-168小时血清浓度-时间曲线下面积(AUC0-168 h)。结果显示Somapacitan暴露随肾/肝损伤程度增加而升高,临床需个体化滴定剂量。

要点

  • 严重肾损伤和血液透析组Somapacitan AUC0-168 h较肾功能正常组升高。
  • 中度肝损伤组Somapacitan AUC0-168 h显著高于肝功能正常组。
  • Somapacitan剂量应根据肾/肝功能个体化滴定。

核心结论

  • Somapacitan暴露随肾或肝损伤程度增加而升高,临床用药需个体化滴定剂量。

研究设计与样本

  • 两项开放标签、平行组、单中心、为期6周的试验。
  • 肾脏试验共44例受试者分为5个肾功能组,肝脏试验共34例受试者分为3个肝功能组。
  • 受试者年龄18-75岁,BMI 18.5-34.9 kg/m²,GH初治且无GHD。
  • 受试者在第1、8、15天接受三次皮下Somapacitan 0.08 mg/kg给药。

主要发现

  • 严重肾损伤组和血液透析组Somapacitan AUC0-168 h较肾功能正常组的估计比值(90% CI)分别为1.75(1.00-3.06)和1.63(1.01-2.61)。
  • 中度肾损伤组、严重肾损伤组和血液透析组IGF-I AUC0-168 h较肾功能正常组的估计比值(90% CI)分别为1.35(1.09-1.66)、1.40(1.10-1.78)和1.24(1.01-1.52)。
  • 中度肝损伤组Somapacitan AUC0-168 h显著高于肝功能正常组,估计比值(90% CI)为4.69(2.92-7.52)。
  • 轻度肝损伤组和中度肝损伤组IGF-I AUC0-168 h较肝功能正常组的估计比值(90% CI)分别为0.85(0.67-1.08)和0.75(0.60-0.95)。
  • 未观察到新的安全性或耐受性问题。

临床怎么用

  • 对伴有肾或肝损伤的GHD成人患者,Somapacitan剂量应基于损伤程度个体化滴定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Somapacitan is a long-acting growth hormone (GH) derivative being developed for once-weekly dosing in patients with GH deficiency (GHD). Our objective was to evaluate the impact of kidney or hepatic impairment on somapacitan exposure in adults. METHODS: In two open-label, parallel-group, single-center, 6-week trials, eligible subjects (18-75 years of age, body mass index 18.5-34.9 kg/m2, GH-naïve, without GHD) were divided into five kidney (total n = 44) or three hepatic (n = 34) function groups. Subjects with normal kidney/hepatic function were matched to those with kidney/hepatic impairment by age, sex, and body weight. Subjects received three subcutaneous somapacitan administrations (0.08 mg/kg) on days 1, 8, and 15. Blood samples were collected before each dose, at 28 time points throughout 2 weeks after the last dose, and at follow-up (3-4 weeks after the last dose). The primary endpoint was area under the somapacitan serum concentration-time curve up to 1 week after the last dose (AUC0-168 h), while secondary endpoints included AUC0-168 h of insulin-like growth factor (IGF)-I. RESULTS: In the kidney impairment trial, somapacitan AUC0-168 h was higher in groups with severe kidney impairment and requiring hemodialysis versus the normal kidney function group (estimated ratio and 90% confidence interval 1.75 [1.00-3.06] and 1.63 [1.01-2.61], respectively). AUC0-168 h of IGF-I was increased in the moderate impairment group (1.35 [1.09-1.66]), severe impairment group (1.40 [1.10-1.78]), and requiring hemodialysis group (1.24 [1.01-1.52]), compared with the normal function group. In the hepatic impairment trial, somapacitan AUC0-168 h was significantly higher in the moderate impairment group compared with the normal hepatic function group (4.69 [2.92-7.52]). IGF-I AUC0-168 h was lower in both hepatic impairment groups (0.85 [0.67-1.08] for the mild impairment group and 0.75 [0.60-0.95] for the moderate impairment group) compared with the normal function group. No new safety or tolerability issues were observed. CONCLUSIONS: In summary, somapacitan exposure increased with level of kidney/hepatic impairment. Clinically, this will be taken into account when treating adults with GHD with somapacitan, as doses should be individually titrated. CLINICAL TRIAL REGISTRATION: NCT03186495 (kidney impairment trial, registered 12 June 2017); NCT03212131 (hepatic impairment trial, registered 30 June 2017). Somapacitan is a long-acting growth hormone molecule for patients with growth hormone deficiency. After its administration as a subcutaneous injection, the action of somapacitan can be affected by kidney or liver disease. Thus, we conducted two trials in which the pharmacokinetic and pharmacodynamic properties of somapacitan were compared between adult subjects with different degrees of worsened kidney or liver function and their healthy counterparts. We found that subjects with severely impaired kidney function and those requiring hemodialysis had a higher somapacitan exposure in blood serum compared with subjects with normal kidney function. The concentration of insulin-like growth factor (IGF)-I, an effector molecule of growth hormone, was also increased with decreased kidney function. In subjects with moderate hepatic function impairment, somapacitan exposure was also higher than those with normal hepatic function; however, the IGF-I concentrations were lower, both at baseline and after dosing with somapacitan. Our results indicate that patients with growth hormone deficiency and kidney or liver disease may need different doses of somapacitan than people with healthy kidneys and/or liver. However, this will be taken into account because somapacitan doses will be individually titrated for each patient with growth hormone deficiency.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Bentz Damholt B, Dombernowsky SL, Dahl Bendtsen M, et al. Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. Clin Pharmacokinet. 2021. PMID: 33754315. doi:10.1007/s40262-021-00990-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。